ProfileGDS5678 / 1452212_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 42% 43% 42% 42% 43% 40% 52% 42% 42% 43% 43% 42% 42% 42% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0021842
GSM967853U87-EV human glioblastoma xenograft - Control 22.9861443
GSM967854U87-EV human glioblastoma xenograft - Control 32.9832642
GSM967855U87-EV human glioblastoma xenograft - Control 42.9207142
GSM967856U87-EV human glioblastoma xenograft - Control 52.9505143
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0208340
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.360752
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9619842
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9573442
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.9748843
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9912343
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9427842
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9775642
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9709942